← Eichor
Condition: Pancreatic Cancer Non Resectable Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pancreatic Cancer Non Resectable

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Phase 2 · 1 location(s) · Fudan University · NCT06359275EUS Procedures Using RIVOS™ EUS Access Device
Phase N/A · 1 location(s) · Orlando Health, Inc. · NCT07696572Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Morten Ladekarl · NCT05841420Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
Phase N/A · 1 location(s) · Englewood Hospital and Medical Center · NCT06937996Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With P
Phase 1/Phase 2 · 1 location(s) · Smartwise Sweden AB · NCT07575191A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
NA · 2 location(s) · Alpha Tau Medical LTD. · NCT05657743Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Chang
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05372614Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2/Phase 3 · 117 location(s) · Exelixis · NCT06943755A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Phase 2 · 1 location(s) · University of Pennsylvania · NCT07199764A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positi
Phase 3 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07066098Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pa
Phase 2 · 26 location(s) · Endevica Bio · NCT06937177Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal
Phase 1 · 46 location(s) · Astellas Pharma Global Development, Inc. · NCT05365581TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancrea
Phase 1 · 1 location(s) · University of California, Davis · NCT07189195ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic C
Phase 1/Phase 2 · 1 location(s) · Anova Innovation Limited · NCT07444541Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Phase 2 · 1 location(s) · National Cancer Center, Korea · NCT06135896Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
NA · 1 location(s) · Fox Chase Cancer Center · NCT06984562Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alon
Phase 2 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT07600268A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advance
Phase 1/Phase 2 · 85 location(s) · GlaxoSmithKline · NCT06885034Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NA · 15 location(s) · Alpha Tau Medical LTD. · NCT06698458Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT06479239Surgery for Locally Unresectable Pancreatic Cancer
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07241663CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.